Rgenta’s A round adds fuel to RNA-targeting small molecule space
$52M round led by AstraZeneca’s joint fund with China International Capital
Rgenta’s latest venture round grows the pool of private funds poured into RNA-targeting small molecules, an area that has seen a steady stream of pharma partnerships since kicking off in 2014, but no disclosed exits or clinical debuts.
On Tuesday, Rgenta Therapeutics Inc. announced a $52 million series A round led by AZ-CICC Healthcare Investment Fund — a private equity fund jointly initiated by AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and China International Capital Corp. — with participation from new investors including Korean Investment Partners and Delos Capital. Also participating were Boehringer Ingelheim Venture Fund, Matrix Partners China, Lilly Asia Ventures and Vivo Capital, who all invested in Rgenta’s 2020 $20 million seed round...